{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:16:25Z","timestamp":1789650985910,"version":"4.0.0"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","award":["Fund 249385"],"award-info":[{"award-number":["Fund 249385"]}],"id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010785","name":"Canada First Research Excellence Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tau is one of several proteins associated with frontotemporal dementia. While knowing which protein is causing a patient\u2019s disease is crucial, no biomarker currently exists for identifying tau in vivo in frontotemporal dementia. The objective of this study was to investigate the potential for the promising 18F-MK-6240 PET tracer to bind to tau in vivo in genetic frontotemporal dementia.<\/jats:p>\n                  <jats:p>We enrolled subjects with genetic frontotemporal dementia, who constitute an ideal population for testing because their pathology is already known based on their mutation. Ten participants (three with symptomatic P301L and R406W MAPT mutations expected to show tau binding, three with presymptomatic MAPT mutations and four with non-tau mutations who acted as disease controls) underwent clinical characterization, tau-PET scanning with 18F-MK-6240, amyloid-PET imaging with 18F-NAV-4694 to rule out confounding Alzheimer\u2019s pathology, and high-resolution structural MRI.<\/jats:p>\n                  <jats:p>Tau-PET scans of all three symptomatic MAPT carriers demonstrated at least mild 18F-MK-6240 binding in expected regions, with particularly strong binding in a subject with an R406W MAPT mutation (known to be associated with Alzheimer\u2019s like neurofibrillary tangles). Two asymptomatic MAPT carriers estimated to be 5 years from disease onset both showed modest 18F-MK-6240 binding, while one \u223c30 years from disease onset did not exhibit any binding. Additionally, four individuals with symptomatic frontotemporal dementia caused by a non-tau mutation were scanned (two C9orf72; one GRN; one VCP): 18F-MK-6240 scans were negative for three subjects, while one advanced C9orf72 case showed minimal regionally non-specific binding. All 10 amyloid-PET scans were negative. Furthermore, a general linear model contrasting genetic frontotemporal dementia subjects to a set of 83 age-matched controls showed significant binding only in the MAPT carriers in selected frontal, temporal and subcortical regions.<\/jats:p>\n                  <jats:p>In summary, our findings demonstrate mild but significant binding of MK-6240 in amyloid-negative P301L and R406W MAPT mutation subjects, with higher standardized uptake value ratio in the R406W mutation associated with the presence of NFTs, and little non-specific binding. These results highlight that a positive 18F-MK-6240 tau-PET does not necessarily imply a diagnosis of Alzheimer\u2019s disease and point towards a potential use for 18F-MK-6240 as a biomarker in certain tauopathies beyond Alzheimer\u2019s, although further patient recruitment and autopsy studies will be necessary to determine clinical applicability.<\/jats:p>","DOI":"10.1093\/brain\/awab392","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:27:20Z","timestamp":1634084840000},"page":"1763-1772","source":"Crossref","is-referenced-by-count":39,"title":["18F-MK-6240 tau-PET in genetic frontotemporal dementia"],"prefix":"10.1093","volume":"145","author":[{"given":"Jake P","family":"Levy","sequence":"first","affiliation":[{"name":"McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University , Montreal, QC H3A 2B4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1069-9201","authenticated-orcid":false,"given":"Gleb","family":"Bezgin","sequence":"additional","affiliation":[{"name":"Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging , Montreal, QC H4H 1R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Savard","sequence":"additional","affiliation":[{"name":"Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging , Montreal, QC H4H 1R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharick A","family":"Pascoal","sequence":"additional","affiliation":[{"name":"Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging , Montreal, QC H4H 1R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Finger","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, Parkwood Institute, Lawson Health Research Institute, University of Western Ontario , London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Robert","family":"Laforce","sequence":"additional","affiliation":[{"name":"Clinique Interdisciplinaire de M\u00e9moire, D\u00e9partement des Sciences Neurologiques du CHU de Qu\u00e9bec, Facult\u00e9 de M\u00e9decine, Universit\u00e9 Laval , Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A","family":"Sonnen","sequence":"additional","affiliation":[{"name":"Departments of Pathology, Neurology and Neurosurgery, Montreal Neurological Institute, McGill University , Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Soucy","sequence":"additional","affiliation":[{"name":"McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University , Montreal, QC H3A 2B4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging , Montreal, QC H4H 1R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Rosa-Neto","sequence":"additional","affiliation":[{"name":"McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University , Montreal, QC H3A 2B4, Canada"},{"name":"Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging , Montreal, QC H4H 1R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-1113","authenticated-orcid":false,"given":"Simon","family":"Ducharme","sequence":"additional","affiliation":[{"name":"McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University , Montreal, QC H3A 2B4, Canada"},{"name":"Department of Psychiatry, Douglas Mental Health University Institute , Montreal, QC H4H 1R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"issue":"18","key":"2022060319045244800_awab392-B1","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000002638","article-title":"Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes","volume":"86","author":"Coyle-Gilchrist","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"2022060319045244800_awab392-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-009-0612-2","article-title":"Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: An update","volume":"119","author":"Mackenzie","year":"2010","journal-title":"Acta Neuropathol"},{"issue":"7","key":"2022060319045244800_awab392-B3","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nrneurol.2017.75","article-title":"Imaging and fluid biomarkers in frontotemporal dementia","volume":"13","author":"Meeter","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"2022060319045244800_awab392-B4","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1093\/brain\/awx254","article-title":"Clinicopathological correlations in behavioural variant frontotemporal dementia","volume":"140","author":"Perry","year":"2017","journal-title":"Brain"},{"issue":"8","key":"2022060319045244800_awab392-B5","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00415-019-09363-4","article-title":"An update on genetic frontotemporal dementia","volume":"266","author":"Greaves","year":"2019","journal-title":"J Neurol"},{"key":"2022060319045244800_awab392-B6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3389\/fnins.2019.00757","article-title":"The use of biomarkers and genetic screening to diagnose frontotemporal dementia: Evidence and clinical implications","volume":"13","author":"Gossye","year":"2019","journal-title":"Front Neurosci"},{"issue":"8","key":"2022060319045244800_awab392-B7","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies-still a challenge","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol Psychiatry"},{"key":"2022060319045244800_awab392-B8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fneur.2018.00070","article-title":"Tau filaments and the development of positron emission tomography tracers","volume":"9","author":"Goedert","year":"2018","journal-title":"Front Neurol"},{"issue":"1","key":"2022060319045244800_awab392-B9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/nan.12213","article-title":"Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: A chameleon for neuropathology and neuroimaging","volume":"41","author":"Ghetti","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"2022060319045244800_awab392-B10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13195-017-0253-y","article-title":"Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain","volume":"9","author":"Ng","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2022060319045244800_awab392-B11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13195-019-0470-7","article-title":"18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes","volume":"11","author":"Tsai","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"2022060319045244800_awab392-B12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1212\/WNL.0000000000003636","article-title":"Frontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations","volume":"88","author":"Spina","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"2022060319045244800_awab392-B13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/jnnp-2019-320904","article-title":"Longitudinal ((18)F)AV-1451 PET imaging in a patient with frontotemporal dementia due to a Q351R MAPT mutation","volume":"91","author":"Convery","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"2022060319045244800_awab392-B14","doi-asserted-by":"crossref","first-page":"e947","DOI":"10.1212\/WNL.0000000000005117","article-title":"In vivo (18)F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms","volume":"90","author":"Jones","year":"2018","journal-title":"Neurology"},{"issue":"10","key":"2022060319045244800_awab392-B15","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/jnnp-2017-316409","article-title":"Flortaucipir tau PET imaging in semantic variant primary progressive aphasia","volume":"89","author":"Makaretz","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"2022060319045244800_awab392-B16","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/jnnp-2017-316402","article-title":"[18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia","volume":"89","author":"Bevan-Jones","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"2022060319045244800_awab392-B17","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/acn3.631","article-title":"18)F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion","volume":"5","author":"Bevan-Jones","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"2022060319045244800_awab392-B18","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00259-019-04631-x","article-title":"Binding of [(18)F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients","volume":"47","author":"Schaeverbeke","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2022060319045244800_awab392-B19","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1038\/s41598-019-42625-9","article-title":"18)F-Flortaucipir in TDP-43 associated frontotemporal dementia","volume":"9","author":"Smith","year":"2019","journal-title":"Sci Rep"},{"issue":"11","key":"2022060319045244800_awab392-B20","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1093\/brain\/awaa276","article-title":"18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases","volume":"143","author":"Soleimani-Meigooni","year":"2020","journal-title":"Brain"},{"issue":"1","key":"2022060319045244800_awab392-B21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40478-018-0535-z","article-title":"Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias","volume":"6","author":"Wren","year":"2018","journal-title":"Acta Neuropathol Commun"},{"issue":"Pt 9","key":"2022060319045244800_awab392-B22","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1093\/brain\/aww163","article-title":"18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers","volume":"139","author":"Smith","year":"2016","journal-title":"Brain"},{"issue":"12","key":"2022060319045244800_awab392-B23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.nucmedbio.2015.08.006","article-title":"Identification of a major radiometabolite of [11C]PBB3","volume":"42","author":"Hashimoto","year":"2015","journal-title":"Nucl Med Biol"},{"issue":"4","key":"2022060319045244800_awab392-B24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","article-title":"Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions","volume":"14","author":"Villemagne","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"2022060319045244800_awab392-B25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jlcr.3890","article-title":"Radiosynthesis and quality control testing of the tau imaging positron emission tomography tracer [(18) F]PM-PBB3 for clinical applications","volume":"64","author":"Kawamura","year":"2021","journal-title":"J Labelled Comp Radiopharm"},{"issue":"1","key":"2022060319045244800_awab392-B26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuron.2020.09.042","article-title":"High-contrast in vivo imaging of tau pathologies in Alzheimer's and non-Alzheimer's disease tauopathies","volume":"109","author":"Tagai","year":"2021","journal-title":"Neuron"},{"key":"2022060319045244800_awab392-B27","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1177\/0271678X211018904","article-title":"Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET","author":"Song","year":"2021","journal-title":"J Cereb Blood Flow Metab"},{"issue":"10","key":"2022060319045244800_awab392-B28","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1021\/acs.jmedchem.6b00166","article-title":"Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs)","volume":"59","author":"Walji","year":"2016","journal-title":"J Med Chem"},{"issue":"10","key":"2022060319045244800_awab392-B29","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","article-title":"Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles","volume":"57","author":"Hostetler","year":"2016","journal-title":"J Nucl Med"},{"issue":"1","key":"2022060319045244800_awab392-B30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11307-019-01367-w","article-title":"Preclinical safety evaluation and human dosimetry of [(18)F]MK-6240, a novel PET tracer for imaging neurofibrillary tangles","volume":"22","author":"Koole","year":"2019","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"2022060319045244800_awab392-B31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2967\/jnumed.118.208215","article-title":"Brain imaging of Alzheimer dementia patients and elderly controls with (18)F-MK-6240, a PET tracer targeting neurofibrillary tangles","volume":"60","author":"Lohith","year":"2019","journal-title":"J Nucl Med"},{"issue":"1","key":"2022060319045244800_awab392-B32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2967\/jnumed.118.209650","article-title":"In vivo characterization and quantification of neurofibrillary Tau PET Radioligand (18)F-MK-6240 in humans from Alzheimer disease dementia to young controls","volume":"60","author":"Betthauser","year":"2019","journal-title":"J Nucl Med"},{"issue":"9","key":"2022060319045244800_awab392-B33","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1093\/brain\/awaa180","article-title":"18F-MK-6240 PET for early and late detection of neurofibrillary tangles","volume":"143","author":"Pascoal","year":"2020","journal-title":"Brain"},{"issue":"1","key":"2022060319045244800_awab392-B34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40478-019-0686-6","article-title":"Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue","volume":"7","author":"Aguero","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"2022060319045244800_awab392-B35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/alz.12033","article-title":"Utility of the global CDR(\u00ae) plus NACC FTLD rating and development of scoring rules: Data from the ARTFL\/LEFFTDS Consortium","volume":"16","author":"Miyagawa","year":"2020","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2022060319045244800_awab392-B36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13195-018-0402-y","article-title":"In vivo quantification of neurofibrillary tangles with [(18)F]MK-6240","volume":"10","author":"Pascoal","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"2022060319045244800_awab392-B37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.111.094029","article-title":"Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand","volume":"53","author":"Cselenyi","year":"2012","journal-title":"J Nucl Med"},{"issue":"4","key":"2022060319045244800_awab392-B38","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","article-title":"Association of apolipoprotein E epsilon4 with medial temporal tau independent of amyloid-beta","volume":"77","author":"Therriault","year":"2019","journal-title":"JAMA Neurol"},{"issue":"2","key":"2022060319045244800_awab392-B39","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/mp.2016.37","article-title":"Amyloid-beta and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease","volume":"22","author":"Pascoal","year":"2017","journal-title":"Mol Psychiatry"},{"issue":"1","key":"2022060319045244800_awab392-B40","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1212\/NXG.0000000000000216","article-title":"CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem","volume":"4","author":"Benedet","year":"2018","journal-title":"Neurol Genet"},{"issue":"6","key":"2022060319045244800_awab392-B41","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1109\/TMI.2010.2046908","article-title":"N4ITK: Improved N3 bias correction","volume":"29","author":"Tustison","year":"2010","journal-title":"IEEE Trans Med Imaging"},{"issue":"2","key":"2022060319045244800_awab392-B42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/nimg.1995.1012","article-title":"A probabilistic atlas of the human brain: Theory and rationale for its development. The International Consortium for Brain Mapping (ICBM)","volume":"2","author":"Mazziotta","year":"1995","journal-title":"NeuroImage"},{"issue":"4 Pt 1","key":"2022060319045244800_awab392-B43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1006\/nimg.1997.0265","article-title":"MRI and PET coregistration\u2013a cross validation of statistical parametric mapping and automated image registration","volume":"5","author":"Kiebel","year":"1997","journal-title":"NeuroImage"},{"issue":"6","key":"2022060319045244800_awab392-B44","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s00259-011-1745-9","article-title":"The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease","volume":"38","author":"Thomas","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2022060319045244800_awab392-B45","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O","article-title":"A unified statistical approach for determining significant signals in images of cerebral activation","volume":"4","author":"Worsley","year":"1996","journal-title":"Hum Brain Mapp"},{"key":"2022060319045244800_awab392-B46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fninf.2016.00020","article-title":"VoxelStats: A MATLAB package for multi-modal voxel-wise brain image analysis","volume":"10","author":"Mathotaarachchi","year":"2016","journal-title":"Front Neuroinform"},{"key":"2022060319045244800_awab392-B47","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fnagi.2014.00264","article-title":"The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer's disease","volume":"6","author":"Voevodskaya","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"2022060319045244800_awab392-B48","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neurobiolaging.2017.10.008","article-title":"Patterns of gray matter atrophy in genetic frontotemporal dementia: Results from the GENFI study","volume":"62","author":"Cash","year":"2018","journal-title":"Neurobiol Aging"},{"issue":"2","key":"2022060319045244800_awab392-B49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(19)30394-1","article-title":"Age at symptom onset and death and disease duration in genetic frontotemporal dementia: An international retrospective cohort study","volume":"19","author":"Moore","year":"2020","journal-title":"Lancet Neurol"},{"issue":"2","key":"2022060319045244800_awab392-B50","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00401-012-1048-7","article-title":"Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion","volume":"125","author":"Bieniek","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2022060319045244800_awab392-B51","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13195-017-0330-2","article-title":"Slowly progressive dementia caused by MAPT R406W mutations: Longitudinal report on a new kindred and systematic review","volume":"10","author":"Ygland","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"3-4","key":"2022060319045244800_awab392-B52","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000480077","article-title":"Frontotemporal dementia caused by the P301L mutation in the MAPT Gene: Clinicopathological features of 13 cases from the same geographical origin in Barcelona, Spain","volume":"44","author":"Borrego-Ecija","year":"2017","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"3","key":"2022060319045244800_awab392-B53","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/nan.12367","article-title":"Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy","volume":"43","author":"Tacik","year":"2017","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"2022060319045244800_awab392-B54","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/brain\/awz378","article-title":"Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age","volume":"143","author":"Betthauser","year":"2020","journal-title":"Brain"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awab392\/43362804\/awab392.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/145\/5\/1763\/43948482\/awab392.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/145\/5\/1763\/43948482\/awab392.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T15:07:15Z","timestamp":1654268835000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/145\/5\/1763\/6402002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,10,19]]},"published-print":{"date-parts":[[2022,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awab392","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,10,19]]}}}